COVID-19 Announcement & Special Funding Opportunities

Mar. 13, 2020 | DRIVe
COVID-19 Special Announcement of Funding Opportunities: (View PDF Flyer)
If your company is developing therapeutics, vaccines, or other products (e.g. software platformswearable technologiespersonal protective equipment, etc.) that could help combat the COVID-19 pandemic, please see below for potential opportunities for partnership and funding!
The Office of Biomedical Advanced Research and Development Authority (BARDA) is supporting the U.S. Government to identify medical countermeasures with the potential to help address the COVID-19 outbreak. Read about current partnerships here! Follow BARDA on Twitter (@BARDA) and on LinkedIn for the most up to date news.
BARDA BAA: COVID-19 Areas of Interest 
BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). Specifically, BARDA is pursuing the following products or technologies:

  • Diagnostic assays for human pan-coronaviruses
  • Vaccines for novel coronavirus
  • Therapeutics for novel coronavirus
  • Ventilators
  • Immunomodulators or therapeutics targeting lung repair
  • Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure
  • Respiratory protective devices

To learn more, including targets for product maturity under this announcement, see the newly revised BARDA Broad Agency Announcement.

Novel Coronavirus EZ-BAA
To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) for molecular diagnostics and nonclinical assays. The diagnostics must leverage FDA-cleared platforms and have a viable plan to meet requirements for the FDA to consider Emergency Use Authorization within 12 weeks of an award.  To learn more, see the Novel Coronavirus EZ-BAA.
2019 Novel Coronavirus Federal Market Research Initiative 
If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners! The federal government established a single point of entry for product developers to submit their research on 2019 novel coronavirus medical countermeasures. Submit a brief description and supporting materials through our Market Research Initiative.



More Information about BARDA and DRIVe:

In 2019, the Biomedical Advanced Research and Development Authority (BARDA) expanded their Division of Research, Innovation, and Ventures (DRIVe) to stimulate investment and innovation in health security products and technologies. DRIVe provides technical and financial resources to entrepreneurs whose ideas have the potential to transform emergency preparedness, detection, and response.

Life Science Washington Institute has been selected as one of 13 sites in the DRIVe accelerator network to identify inventors and connect them with resources that will enable earlier treatment and warning for communities against outbreaks.

To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation’s health security. To learn more about preparing for and responding to public health emergencies, visit the HHS public health emergency website, For more information on partnering with BARDA on developing medical countermeasures, visit, and for more on DRIVe, visit

Comments are closed.